Liminatus Pharma, Inc. Class A Common Stock (LIMN) Stock Price

LIMNStock

$4.23−96.93%52W

Market Cap$5.68M

P/E—

PEG Ratio—

Div yield—

Beta0.76

LIMN Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-75.53%

Price vs S&P 500 (4W)-27.07%

VGM Score7.12

Industry Peers — Biological Products(183)

Symbol	Value Score	Growth Score	Momentum Score	Price
LIMNLiminatus Pharma, Inc. Class A Common Stock	—	—	F	$4.23
AMGNAmgen Inc	C	C	B	$432.42
GILDGilead Sciences Inc	C	B	B	$145.68
ARGXargenx SE American Depositary Shares	D	A	B	$1023.21
MRNAModerna, Inc. Common Stock	D	C	A	$137.99
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$207.88
BIIBBiogen Inc. Common Stock	C	D	B	$218.50
BNTXBioNTech SE American Depositary Share	C	C	C	$102.08
NBIXNeurocrine Biosciences Inc	C	B	C	$154.06
EXELExelixis Inc	C	B	B	$54.45
HALOHalozyme Therapeutics, Inc.	C	B	B	$105.35
TECHBio-Techne Corp.	D	C	B	$72.35
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$351.46
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	$134.97
RGENRepligen Corp	D	C	B	$176.27
KYMRKymera Therapeutics, Inc. Common Stock	D	B	B	$118.15
PCVXVaxcyte, Inc. Common Stock	—	—	B	$59.84
QGENQIAGEN N.V.	C	C	B	$43.11
TWSTTwist Bioscience Corporation Common Stock	D	B	A	$141.38
IBRXImmunityBio, Inc. Common Stock	F	A	B	$8.05
IMVTImmunovant, Inc. Common Stock	—	—	B	$41.20
SRRKScholar Rock Holding Corporation Common Stock	F	—	B	$57.80
CGONCG Oncology, Inc. Common stock	F	A	B	$74.34
CRSPCRISPR Therapeutics AG	D	B	C	$57.72
RLAYRelay Therapeutics, Inc. Common Stock	F	D	B	$18.77
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	A	$25.19
DNLIDenali Therapeutics Inc. Common Stock	F	—	B	$24.00
IOVAIovance Biotherapeutics, Inc. Common Stock	C	B	A	$8.01
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	$71.76
BEAMBeam Therapeutics Inc. Common Stock	C	B	B	$29.32
BCRXBioCryst Pharmaceuticals Inc	B	A	B	$9.82
KODKodiak Sciences Inc Common Stock	—	—	B	$37.72
MESOMesoblast Limited American Depositary Shares	D	B	B	$17.44
VCELVericel Corporation	D	B	B	$40.95
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	B	$44.84
ADMAADMA Biologics, Inc.	C	C	C	$9.34
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	$36.62
TSHATaysha Gene Therapies, Inc. Common Stock	F	B	B	$5.77
VIRVir Biotechnology, Inc. Common Stock	B	B	B	$10.83
INBXInhibrx Biosciences, Inc. Common Stock	D	C	A	$123.41
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	$3.34
ALVOAlvotech Ordinary Shares	C	D	C	$4.95
NVAXNovavax Inc	B	D	C	$9.26
MAZEMaze Therapeutics, Inc. Common Stock	—	—	C	$27.44
SLBTSL Science Holding Limited Ordinary Shares	—	—	C	$2.70
REPLReplimune Group, Inc.	—	—	A	$15.50
IMTXImmatics N.V. Ordinary Shares	C	D	C	$9.45
VORVor Biopharma Inc. Common Stock	—	—	B	$22.65
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	A	$21.70
MGTXMeiraGTx Holdings plc Ordinary Shares	D	C	B	$13.82
SANASana Biotechnology, Inc. Common Stock	—	—	B	$3.93

About Liminatus Pharma, Inc. Class A Common Stock

Liminatus Pharma is a clinical-stage biopharmaceutical company developing the GCC Vaccine, an immunotherapy targeting cancers that express Guanylyl Cyclase C. The vaccine candidate is currently in Phase II clinical trials for colorectal, pancreatic, gastric, and esophageal cancers.